SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...
Four years ago, my life changed after a heart attack at the age of 33. While a quick coronary angioplasty meant my heart was mostly fine, the tests conducted at the same time revealed a bigger chronic ...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom ...
San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...
DexCom's not just a diabetes company anymore. They're at the forefront of wearable health tech, blurring the lines between medicine and lifestyle. DexCom might not be the flashiest stock, but their ...
Shares of DexCom DXCM lost almost 3% on Jun 3, probably due to concerns about a rise in competition for its recently approved Stelo as the FDA approved a competing product. The FDA approval for Stelo ...
Shares of DexCom DXCM lost almost 3% on Jun 3, probably due to concerns about a rise in competition for its recently approved Stelo as the FDA approved a competing product. The FDA approval for Stelo ...
Stelo offers powerful and personalized glucose insights directly to a smartphone, revealing how food, exercise and sleep can affect glucose – all without painful fingersticks. (Photo: Dexcom) Stelo is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback